Anne Le Moigne, MS
Global Research & Development, Indivior Inc., North Chesterfield, Virginia; Corresponding author: Anne Le Moigne, MD, Clinical/Data Sciences and Operations, Indivior Inc., 10710 Midlothian Turnpike, Ste 125, North Chesterfield, VA 23235 ([email protected]).
Original Research
Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis
September 21, 2021
Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
